LipTx™ NV3-006 Ionizable Lipid

PRODUCT OVERVIEW​​

Quality Grade: Research Use Only (RUO) (GMP on request)​

Target pKa Window: 6.4 – 7.0

Molecular Weight: 927.58 g/mol

Purity: ≥ 95%

Appearance: Pale yellow, viscous liquid

​

TECHNICAL SPECIFICATIONS

Solubility: Max. 50 mg/mL: EtOH, MeOH, chloroform, IPA, DMSO

Modular Molecular Platform Blocks: Novel ionizable lipid engineered with orthogonally oriented ionizable centers linked to saturated carbon tails to improve the stability.

​

Encapsulation Efficiency: >90% across complex nucleic acid cargos (pDNA, siRNA, mRNA, and CRISPR-Cas systems)

Thermostability: No degradation observed at following conditions: 20°C for 1 month, 2-8 °C for 1 week, 25 °C for 24 hours and 50 °C for half an hour

​

ORDERING INFORMATION

Lead Times: Gram production: 6–8 weeks; GMP-grade material: 6–12 months

​

STORAGE & STABILITY

Storage Environment: Store at –80 ± 5 °C in the original, tightly closed container. Protect from moisture, oxygen, and prolonged light exposure. Minimize freeze-thaw cycles

Shelf Life: 12 months at –80 °C (retest of assay and impurities for extension)

PRODUCT DESCRIPTION​

LipTx™ NV3-006 is a proprietary ionizable lipid developed by NeoVac for nucleic acid delivery applications within the LipTx™ Ionizable Lipid Platform. The lipid is engineered to remain predominantly neutral at physiological pH (7.4) and to switch to a protonated, positively charged state under the acidic conditions encountered in the endosome. This mechanism drives efficient nucleic acid encapsulation during lipid nanoparticle (LNP) manufacturing and potent endosomal release for intracellular delivery. This ionizable lipid is also available as a core component of the LipTx™ NV3-006 Formulation Kit, which can be sourced in 2 ml, 5 ml, and 10 ml configurations.

​

RELEVANT APPLICATIONS

LNP formulation, mRNA vaccines, mRNA therapeutics, siRNA delivery, protein replacement therapy, gene therapy and in-vivo genome editing, CRISPR-Cas ribonucleoprotein / mRNA delivery, ex vivo cell therapy (e.g., CAR-T), formulation screening, academic and preclinical research.

​

RELEVANT PROCESS STEPS

mRNA-LNP / nucleic acid-LNP formulation, drug product formulation and process development, formulation screening across N/P ratios and lipid compositions, delivery / transfection studies, analytical characterization and stability assessment.